Search Results

You are looking at 181 - 190 of 490 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes

intravenous paclitaxel/carboplatin or docetaxel/carboplatin. 143 Fertility-sparing surgery and/or observation/monitoring are options for patients with unilateral clear cell borderline tumors (see LCOH-6; page 1141). For patients with stage II to IV clear cell

Full access

Stereotactic Body Radiation Therapy: A New Standard Option for Pancreatic Cancer?

Joseph M. Herman and Albert C. Koong

cancer. In addition, multiagent chemotherapy regimens such as FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin) and gemcitabine with nab-paclitaxel have resulted in significant improvements in survival when compared to gemcitabine monotherapy

Full access

Biomarker-Based Treatment Selection in Non–Small Cell Lung Cancer

Wallace Akerley

gefitinib (an EGFR inhibitor) versus carboplatin/paclitaxel ( P <.001), whereas those who were EGFR -negative had significantly improved PFS on carboplatin/paclitaxel versus gefitinib ( P <.001). 2 “This early study showed that PFS was significantly

Full access

In Chemotherapy for Lung Cancer, Sometimes Less is More

Eric Roeland, Charles Loprinzi, Timothy J. Moynihan, Thomas J. Smith, and Jennifer Temel

cytotoxic agents in patients in similar settings: 2 months for bevacizumab when added to carboplatin/paclitaxel and 2.6 months for maintenance pemetrexed. 17 , 18 Although the possibility of prolonged survival with supportive care interventions has been

Full access

Ten Years of Progress in Non–Small Cell Lung Cancer

David S. Ettinger

empiric, usually a platinum-based doublet. However in 2006, the FDA approved use of the anti-vascular endothelial growth factor monoclonal antibody, bevacizumab, with paclitaxel and carboplatin (PCB). This approval was based on the results of the ECOG

Full access

Supportive Care in Head and Neck Cancers: Multidisciplinary Management

Presented by: Jimmy J. Caudell, David G. Pfister, and Randal S. Weber

chemotherapy (as was the standard at the time) with carboplatin and paclitaxel for 2 cycles. According to Dr. Caudell, this patient did well for years, but in 2019 presented with perceived slurring of speech. On examination, his tongue deviated to the right

Full access

The Role of Inhibitors of the Epidermal Growth Factor in Management of Head and Neck Cancer

Bruce Brockstein, Mario Lacouture, and Mark Agulnik

Edited by Kerrin G. Robinson

. Hitt R Irigoyen A Nunez J . Phase II study of combination cetuximab plus weekly paclitaxel in patients with recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN) [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1 ): Abstract 6012

Full access

Bladder Cancer

James E. Montie, Peter E. Clark, Mario A. Eisenberger, Rizk El-Galley, Richard E. Greenberg, Harry W. Herr, Gary R. Hudes, Deborah A. Kuban, Timothy M. Kuzel, Paul H. Lange, Subodh M. Lele, Jeffrey Michalski, Anthony Patterson, Kamal S. Pohar, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Donald L. Trump, Phillip J. Walther, and Timothy G. Wilson

. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial . J Urol 2000 ; 164 : 53 – 56 . 49 Meluch AA Greco FA Burris HA III . Paclitaxel and gemcitabine chemotherapy for advanced

Full access

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli II, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Jayanthi Lea, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, Shaili Aggarwal, and Sara Espinosa

radiosensitizing agents that could be considered for use only when cisplatin and carboplatin are unavailable (see CERV-F 1 of 3 , above). The options of capecitabine/mitomycin, gemcitabine, and paclitaxel were added under “Other Recommended Regimens” as

Full access

First-Line Systemic Therapy Practice Patterns and Concordance With NCCN Guidelines for Patients Diagnosed With Metastatic NSCLC Treated at NCCN Institutions

Carrie Zornosa, Jonathan L. Vandergrift, Gregory P. Kalemkerian, David S. Ettinger, Michael S. Rabin, Mary Reid, Gregory A. Otterson, Marianna Koczywas, Thomas A. D'Amico, Joyce C. Niland, Rizvan Mamet, and Katherine M. Pisters

platinum-based regimens varied from 4% to 22%. Table 2 Off-Trial First-Line Systemic Drug Therapy Combinations Used According to Therapy Type (n = 1131) Paclitaxel was the most common cytotoxic partner agent combined with a platinum agent (n